Novavax (NVAX) Other Non-Current Liabilities (2010 - 2026)

Novavax's Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $193.2 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 38.4% year-over-year to $193.2 million in Q1 2026; TTM through Mar 2026 was $193.2 million, a 38.4% decrease from a year earlier, with the FY2025 full-year figure at $239.1 million, down 33.52% from the prior year.
• Other Non-Current Liabilities eased to $193.2 million in Q1 2026 per NVAX's latest filing, from $239.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $359.6 million in Q4 2024 and bottomed at $33.1 million in Q4 2023.
• The 5-year median for Other Non-Current Liabilities is $193.2 million (2026), against an average of $182.9 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 62.16% in 2023 and jumped 985.46% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $55.7 million in 2022, then plunged by 40.52% to $33.1 million in 2023, then soared by 985.46% to $359.6 million in 2024, then plunged by 33.52% to $239.1 million in 2025, then retreated by 19.17% to $193.2 million in 2026.
• Per Business Quant, the three latest NVAX Other Non-Current Liabilities figures stand at $193.2 million (Q1 2026), $239.1 million (Q4 2025), and $263.5 million (Q3 2025).